Molecular Mechanisms of Ovarian Steroid Receptor Action in Cancers and Tumors
G protein-coupled estrogen receptor 1 (GPER1)-mediated tamoxifen action in breast cancer
The Selective Estrogen Receptor Modulator (SERM), tamoxifen, acts as an ERα antagonist in breast cancer and is the most widely used adjuvant treatment for breast cancer patients. However, some breast cancers are insensitive to tamoxifen treatment and most breast cancers develop resistance over time. Tamoxifen is an agonist for the membrane-bound G protein-coupled estrogen receptor 1 (GPER1) and this receptor has been implicated in the acquisition of tamoxifen resistance in breast cancer cells. Little is known about the molecular mechanisms underlying the altered sensitivity. The working hypothesis in my group is that GPER1 plays an important factor of the sensitivity of breast cancer cells to tamoxifen. A major research goal in my laboratory is to define the role of GPER1 in tamoxifen treated breast cancer cells.
Currently Funded by:
Previously Funded by:
New Mexico INBRE
Collaborative Projects
Using metabolic alterations associated with cancer for label-free measurements by flow cytometry
w/ Jessica P. Houston, Department of Chemical and Materials Engineering, New Mexico State University
Previously Funded by:
